Teva Pharmaceutical Industries Ltd. will seek to overhaul its board by nominating four new directors, the latest step toward remaking the struggling drug company. Teva, the world’s biggest seller of low-price generic drugs, will ask shareholders to approve the nominees at the company’s annual meeting July 13, said Sol Barer, the board’s chairman. The nominees would replace longtime board members who have decided to step aside or...

Source: Wall Street Journal June 08, 2017 20:03 UTC